ES2055904T3 - Composiciones para suministro de farmacos. - Google Patents

Composiciones para suministro de farmacos.

Info

Publication number
ES2055904T3
ES2055904T3 ES90903612T ES90903612T ES2055904T3 ES 2055904 T3 ES2055904 T3 ES 2055904T3 ES 90903612 T ES90903612 T ES 90903612T ES 90903612 T ES90903612 T ES 90903612T ES 2055904 T3 ES2055904 T3 ES 2055904T3
Authority
ES
Spain
Prior art keywords
drugs
compositions
supply
composition
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90903612T
Other languages
English (en)
Other versions
ES2055904T5 (es
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10652342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2055904(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Application granted granted Critical
Publication of ES2055904T3 publication Critical patent/ES2055904T3/es
Publication of ES2055904T5 publication Critical patent/ES2055904T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

UNA COMPOSICION PARA ADMINISTRAR EN LA MUCOSA CONSTA DE UN COMPUESTO FARMACOLOGICAMENTE ACTIVO Y UNA SUSTANCIA POLICATIONICA. LA SUSTANCIA POLICATIONICA ES PREFERIBLEMENTE ES DEXTRANO-DEAE O QUITOSANO Y EL COMPUESTO FARMACOLOGICAMENTE ACTIVO ES PREFERIBLEMENTE INSULINA O CLACITONINA. LA COMPOSICION PUEDE PRESENTARSE COMO SOLUCION, DISPERSION, POLVO O MICROESFERAS. OTROS INTENSIFICADORES, TAL COMO LISOFOSFATIDILCOLINA PUEDEN INCLUIRSE SI SE DESEA.
ES90903612T 1989-02-25 1990-02-23 Composiciones para suministro de farmacos. Expired - Lifetime ES2055904T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898904370A GB8904370D0 (en) 1989-02-25 1989-02-25 Liquid delivery compositions

Publications (2)

Publication Number Publication Date
ES2055904T3 true ES2055904T3 (es) 1994-09-01
ES2055904T5 ES2055904T5 (es) 1998-01-01

Family

ID=10652342

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90903612T Expired - Lifetime ES2055904T5 (es) 1989-02-25 1990-02-23 Composiciones para suministro de farmacos.

Country Status (10)

Country Link
EP (1) EP0460020B2 (es)
JP (1) JP3306779B2 (es)
AT (1) ATE104545T1 (es)
CA (1) CA2045472C (es)
DE (1) DE69008346T3 (es)
DK (1) DK0460020T3 (es)
ES (1) ES2055904T5 (es)
GB (1) GB8904370D0 (es)
NO (1) NO301692B1 (es)
WO (1) WO1990009780A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU653771B2 (en) * 1991-01-03 1994-10-13 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6054462A (en) * 1994-04-13 2000-04-25 Janssen Pharmaceutica, N.V. Intranasal antimigraine compositions
HRP950149A2 (en) * 1994-04-13 1997-06-30 Janssen Pharmaceutica Nv Intranasal antimigrene composition
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
SE9403905D0 (sv) * 1994-11-14 1994-11-14 Astra Ab New formulations
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
JP3020141B2 (ja) * 1996-10-07 2000-03-15 株式会社富士薬品 経鼻投与用製剤
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
US6730735B2 (en) 1997-07-03 2004-05-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Conjugate of polyethylene glycol and chitosan
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
EP1637154A3 (en) * 1998-07-08 2007-08-15 Kirin-Amgen Inc. High molecular weight medicine-containing preparation in powder form for administration through mucosa
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CN1543338B (zh) 2001-08-16 2010-06-16 Cmp医疗有限公司 壳多糖微粒及其医疗用途
KR20040071678A (ko) * 2001-09-28 2004-08-12 유니버시티 오브 사우스 플로리다 Ｒｓｖ 유전자 발현 백신
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
CA2484251C (en) 2002-04-30 2015-06-23 University Of South Florida Materials and methods for inhibition of respiratory syncytial virus infection
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0310919D0 (en) 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
US8399025B2 (en) 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
EP1797870A1 (en) * 2005-12-14 2007-06-20 The Jordanian Pharmaceutical Manufacturing Co. Oral delivery of protein drugs using microemulsion
AU2007285472B2 (en) 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
WO2007148048A1 (en) 2006-06-20 2007-12-27 Cmp Therapeutics Limited Compositions comprising chitin microparticles and their medical uses
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
WO2009026122A1 (en) * 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
MX2012005961A (es) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizador.
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
RS58985B1 (sr) * 2012-03-15 2019-08-30 Acraf Katjonski polimeri na bazi glikogena
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
WO2014055825A1 (en) 2012-10-04 2014-04-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A formulation of mycobacterial components as an adjuvant for inducing th17 responses
US10258682B2 (en) 2013-01-16 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
BR122022010094B1 (pt) 2014-05-07 2023-10-03 Boehringer Ingelheim International Gmbh Dispositivo indicador e recipiente
MX383195B (es) 2014-05-07 2025-03-13 Boehringer Ingelheim Int Recipiente, nebulizador y uso.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3250023T (es) * 1981-01-14 1990-03-29

Also Published As

Publication number Publication date
EP0460020B1 (en) 1994-04-20
NO912870D0 (no) 1991-07-23
NO912870L (no) 1991-07-23
EP0460020A1 (en) 1991-12-11
ES2055904T5 (es) 1998-01-01
DE69008346T2 (de) 1994-08-25
EP0460020B2 (en) 1997-09-17
GB8904370D0 (en) 1989-04-12
DE69008346T3 (de) 1998-01-08
WO1990009780A1 (en) 1990-09-07
CA2045472A1 (en) 1990-08-26
CA2045472C (en) 2000-01-04
DK0460020T3 (da) 1994-05-16
DE69008346D1 (de) 1994-05-26
JP3306779B2 (ja) 2002-07-24
ATE104545T1 (de) 1994-05-15
NO301692B1 (no) 1997-12-01

Similar Documents

Publication Publication Date Title
ES2055904T5 (es) Composiciones para suministro de farmacos.
AU587281B2 (en) Slow-release pharmaceutical agent
IL114596A (en) Pharmaceutical compositions containing an active substance blended with a carrier process for preparation thereof and their use for preparation of inhalated drugs
NO954582L (no) Blanding for nasal administrering av nikotin
IE863420L (en) Xanthan gum sustained drug release composition
BR9911070A (pt) Sistema de liberação de droga compreendendo uma matéria-prima de medicamento sólido acentuadamente compacto
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
NO870558L (no) Fremgangsmaate for fremstilling av et langsomt frigivende farmasoeytisk preparat.
MX171463B (es) Sistema de dosificacion de liberacion sostenida y procedimiento para su preparacion
JO1502B1 (en) New pharmacy vehicles
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
KR880010758A (ko) 서방성 제제
BR9809268A (pt) Unidade de dosagem farmacêutica, processo para fabricação da mesma, e, uso de um produto de amido como um veìculo para unidades de dosagem farmacêutica compreendendo tibolona
MY102411A (en) Nasal solutions
DE69225053D1 (de) Zusammensetzungen auf der basis von collagen zur kontrollierten arzneistoffreisetzung
ES2036609T3 (es) Granulado exento de aglutinante con lubricacion retardada del producto activo.
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
BR9710629A (pt) Composi-Æo farmac-utica processo para sua prepara-Æo composto para utiliza-Æo como agente terap-utico e utiliza-Æo e utiliza-Æo de um composto
KR920016104A (ko) 노인성 특발적 백내장 약제 제조를 위한 칼시토닌의 국소적용 용도 및 이의 약제학적 조성물
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
JO1531B1 (en) New near-compounds

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460020

Country of ref document: ES